|

CapeOx Clinical Trials

7 actively recruiting trials across 1 location

No change since May 2026

Also known as: Capecitabine, Capecitabine and oxaliplatin, Oxaliplatin, Surgery

Pipeline

Phase 2: 5Phase 3: 2

Top Sponsors

  • GlaxoSmithKline2
  • Sun Yat-sen University1
  • Ruijin Hospital1
  • Huazhong University of Science and Technology1
  • Fudan University1

Indications

  • Cancer7
  • Neoplasms, Colon2
  • Rectal Cancer2
  • Colonic Neoplasms1
  • Colon Adenocarcinoma1

Other6 trials

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Phase 2
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Phase 2
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
Phase 2
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
Phase 3
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Phase 2
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
Phase 2

Tucson, Arizona1 trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GSK Investigational Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.